ARS Pharmaceuticals, Inc.
NNASDAQ:SPRYCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Donn Casale
- Full Time Employees
- 163
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 11682 El Camino Real San Diego CA United States 92130
- IPO Date
- Dec 4, 2020
- CIK
- 0001671858
- Website
- ars-pharma.com
- Similar Companies
- Business
- ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative treatments for severe allergic reactions, including anaphylaxis. Its primary product offering is neffy®, the first and only FDA-approved needle-free intranasal epinephrine spray designed for the emergency treatment of Type I allergic reactions in adults and children aged 4 years and older who weigh 33 pounds or more. Neffy® combines epinephrine with an absorption enhancer to provide rapid, injection-like absorption in a small, easy-to-use nasal spray, aiming to improve patient and caregiver confidence and prompt administration of epinephrine upon symptom onset. The company also conducts ongoing clinical trials for expanding the use of its intranasal epinephrine technology into additional indications such as chronic spontaneous urticaria. ARS Pharmaceuticals operates primarily in the United States and Europe, with headquarters in San Diego, California. Founded prior to its public listing and presently traded under the ticker SPRY on NASDAQ, the company targets at-risk patients with severe allergies, healthcare providers, and caregivers, offering a patient-friendly alternative to traditional injectable epinephrine products. Recent significant developments for ARS Pharmaceuticals include a strategic licensing agreement with ALK-Abelló A/S, under which ARS received an upfront payment of $145 million and is eligible for up to $320 million in regulatory and commercial milestone payments plus tiered royalties. This partnership assigns ALK responsibility for marketing, local market access, and sales of the neffy® product. In 2025, ARS launched a national direct-to-consumer advertising campaign to increase product awareness, contributing to a 180% increase in weekly prescription volumes of neffy® in the U.S. Furthermore, the company initiated a Phase 2b clinical trial for the treatment of acute flares in chronic spontaneous urticaria, enrolling patients across the U.S. and Europe, with topline data expected in early 2026. ARS has also secured broad commercial payer coverage, achieving 93% commercial coverage in the U.S. including 57% without prior authorization, substantially reducing administrative barriers for providers. Overall, ARS Pharmaceuticals delivers comprehensive allergy treatment solutions through its flagship neffy® nasal spray, supported by robust clinical development programs, strong commercial partnerships, and expanding market access across North America and Europe. The company’s financial position and strategic initiatives position it for continued growth in the biopharmaceutical allergy treatment sector.
Company News
ARS Pharmaceuticals Analysts Cut Their Forecasts After Downbeat Q3 Results
ARS Pharmaceuticals, Inc. (SPRY) Q3 2026 Earnings Call Transcript
ARS Pharmaceuticals Q3 Earnings Call Highlights
ARS Pharmaceuticals, Inc. (SPRY) Reports Q3 Loss, Lags Revenue Estimates
ARS Pharmaceuticals: Lawsuits And Cash Burn Are Priced In, Yet The Stock Keeps Falling
ARS Pharmaceuticals, Inc. (SPRY) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
ARS Pharma to Report Third Quarter 2026 Financial Results
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
SPRY FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
ARS Pharmaceuticals, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SPRY
SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit with SBS Law
ARS PHARMACEUTICALS DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY
SPRY INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
SPRY EQUITY ACTION REMINDER: Faruqi & Faruqi, LLP Reminds ARS Pharmaceuticals Investors of Securities Class Action Lawsuit Deadline on October 5, 2026
ARS PHARMACEUTICALS DEADLINE: ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages ARS Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important October 5 Deadline in Securities Class Action - SPRY
ARS Pharmaceuticals Deadline: SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
ARS PHARMACEUTICALS DEADLINE: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages ARS Pharmaceuticals, Inc. Investors to Secure Counsel Before Important October 5 Deadline in Securities Class Action – SPRY